M&A Deal Summary

Mesoblast Acquires Angioblast Systems

On December 7, 2010, Mesoblast acquired life science company Angioblast Systems

Acquisition Highlights
  • This is Mesoblast’s 1st transaction in the Life Science sector.
  • This is Mesoblast’s 1st transaction in the United States.
  • This is Mesoblast’s 1st transaction in New York.

M&A Deal Summary
Date 2010-12-07
Target Angioblast Systems
Sector Life Science
Buyer(s) Mesoblast
Deal Type Add-on Acquisition

Target

Angioblast Systems

New York, New York, United States
Angioblast Systems, Inc. is a biotechnology company. Angioblast is a provider in the development and commercialization of novel therapeutic products for the treatment of cardiovascular diseases.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Mesoblast

Melbourne, Australia
Category Company
Founded 2004
Sector Life Science
Employees83
Revenue 8M USD (2023)
DESCRIPTION

Mesoblast is a developing biotherapeutics based on its proprietary cell-based and protein technologies. Mesoblast’s technology platforms have the potential to deliver a diverse portfolio of clinical-stage products to treat major conditions with unmet medical needs. Mesoblast was founded in 2004 and is based in Melbourne, Australia.

DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 2
Type (Add-on Acquisition) 1 of 1
State (New York) 1 of 1
Country (United States) 1 of 2
Year (2010) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2013-10-10 Osiris Therapeutics - Mesenchymal Stem Cell Business

Columbia, Maryland, United States

Osiris Therapeutics's Mesenchymal Stem Cell (MSC) Business is a manufacturer of stem cells.

Buy -
Mergr

Product

Company

Legal